Findings from a randomized, double-blind study on interferon beta (IFN-β)-treated patients with MS showed that melatonin secretion is negatively correlated with alterations in serum 25-hydroxyvitamin D3 (25-OH-D3), which may suggest potential interactions between both hormones with beneficial neuro-immunomodulating effects under deteriorated immune responses [74]. The gene discussed is IFNB1; the disease is myeloid sarcoma.